Back to Peptide Library
Tissue Repair Research

BPC-157

Body Protection Compound • 15-Amino-Acid Peptide

BPC-157 is a synthetic peptide investigated for connective-tissue and gastrointestinal repair. The broad animal evidence has not yet established efficacy, dosing, or long-term safety in people.

Routes
Oral / SubQ
Compound type
15-amino-acid peptide
Regulatory status
Not FDA approved
Last reviewed
At a glance

BPC-157 Quick Reference

SubQ community range
Members only
Sign in to view dosing details.
Oral capsules
500mcg capsules
Common product strength, not a validated daily dose
Cycle
Members only
Sign in to view dosing details.
Evidence level
Preclinical
Animal and laboratory findings dominate
Overview

What Is BPC-157?

BPC-157 stands for Body Protection Compound 157. It is a synthetic 15-amino-acid fragment of a larger protein originally identified in human gastric juice. Its sequence is Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val. The manufactured peptide isolates this fragment; it should not be confused with the full gastric protein.

Researchers first described the fragment in 1993. Subsequent animal and laboratory studies explored gastrointestinal protection and repair responses in tendon, ligament, muscle, bone, wounds, and nerves. These findings explain its broad reputation, but they do not establish regeneration or symptom relief in people.

Human evidence remains exceptionally limited. A 2025 review identified only three small pilot studies, covering knee pain, interstitial cystitis, and short-term safety. None establishes an effective oral or SubQ dose, a treatment course, or long-term safety.

BPC-157 is not FDA approved. FDA placed it in its Category 2 compounding-risk group in 2023; the nomination was later withdrawn, while the agency continues to flag limited human safety information and possible formulation risks. WADA added BPC-157 to its S0 prohibited list in 2022, so athletes subject to anti-doping rules should treat it as prohibited.

For other repair- and immune-focused compounds, see ARA-290 and LL-37.

Mechanism

BPC-157 Mechanism of Action

Vascular Signaling

Animal and cell studies suggest effects on VEGF-related signaling, angiogenesis, and tissue perfusion; a human repair pathway is not established.

Nitric Oxide Pathway

Preclinical findings point to interaction with nitric-oxide signaling involved in vascular and injury responses.

Cell Migration

Laboratory models report changes in fibroblast survival and movement that may support connective-tissue organization.

Gut Protection Models

Gastric and intestinal injury models show protective signals. Human oral absorption and therapeutic effects remain uncertain.

Research findings

BPC-157 Benefits

Most proposed benefits come from animal or laboratory experiments. They should not be read as proven human treatment outcomes.

Current evidence level: predominantly preclinical

Tendon & Ligament Repair

Animal studies report changes in tendon healing, fibroblast activity, and connective-tissue organization.

Muscle Recovery

Preclinical injury models suggest improved muscle structure and function during healing.

Gastrointestinal Research

Ulcer and intestinal injury models provide a basis for gut-focused interest; clinical benefit remains unproven.

Nerve & Wound Models

Peripheral-nerve and wound studies suggest repair activity, with little controlled human confirmation.

Protocol planning

BPC-157 Dosing Protocol

Members Access Only

Sign in or create a free account to view this content.

Preparation

BPC-157 Reconstitution

Reconstitution Example

10mg vial + 2mL bacteriostatic water

Result5mg/mL

Reconstitution steps

1
Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2
Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.

3
Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

4
Storage

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

BPC-157 Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

  • Recovery interest. Users describe less pain or irritation during tendon, ligament, and overuse recovery.
  • Gradual changes. Some describe improved movement or training tolerance over several weeks.
  • Stack discussion. BPC-157 plus TB-500 is a frequent community pairing.

Negative & Mixed Reports

  • No clear response. Structural or long-standing injuries may show little change.
  • Oral variability. Capsule reports are mixed and product content varies.
  • Local effects. Injection-site redness or discomfort is commonly reported.
Stacking & synergy

BPC-157 Stacking & Synergy

These are community-discussed combinations, not validated BPC-157 combination protocols. Consider each compound separately when assessing response.

BPC-157 + TB-500

The most common pairing. In preclinical models, BPC-157 promotes new-vessel signaling that may improve nutrient delivery to injured tissue. Thymosin beta-4, the parent peptide of TB-500, regulates actin dynamics and cell migration. These mechanisms are complementary in theory.

BPC-157 + KPV

A gut-focused pairing with distinct research targets: BPC-157 is studied in mucosal injury and repair models, while KPV reduced inflammatory signaling in intestinal cells and mouse colitis models. No controlled study has tested them together.

BPC-157 + GHK-Cu

Community rationale combines repair signaling with collagen and extracellular-matrix interest; additive benefit is unproven.

Safety notes

BPC-157 Side Effects & Safety

Human safety data are too limited to define a reliable adverse-effect profile for oral or SubQ use.

FDA flags possible immunogenicity, peptide impurities, and insufficient route-specific human safety information.

Community Reports

  • Injection-site redness, swelling, or discomfort.
  • Nausea, headache, dizziness, or fatigue.
  • Oral product quality and tolerability vary.

Unresolved Risks

  • Immune reactions and contamination risks with injectable formulations.
  • Long-term human effects are unknown.
  • Preclinical vascular-signaling findings do not settle cancer-related safety questions.

BPC-157 Precautions

Avoid or Discuss With a Clinician If
  • Known allergy to the peptide or formulation components.
  • Pregnant or breastfeeding; human safety data are lacking.
  • Active cancer, unresolved masses, or significant medical illness.
Use caution with
  • Other treatments that could complicate symptom or adverse-event tracking.
  • Unverified products or assumptions that oral and injectable doses are interchangeable.
Regulatory status: BPC-157 is not FDA approved for human therapeutic use and is prohibited for athletes subject to WADA rules.
Final verdict

Peptide Protocols Verdict on BPC-157

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion

Our take on BPC-157 comes from using it in KLOW and GLOW, and in oral capsules paired with KPV. We have not used BPC-157 on its own, so we cannot separate its contribution from the other compounds.

The capsule pairing made a clear difference in our gut health. With GLOW, regular shoulder pain resolved. Those personal results are the reason BPC-157 has stayed on our radar, even though neither experience tells us which ingredient did the work.

We give BPC-157 a B because our experience has been positive and the preclinical research is interesting. We still want controlled human studies before making confident claims about what BPC-157 alone can do.